BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 38218922)

  • 1. Akt enhances the vulnerability of cancer cells to VCP/p97 inhibition-mediated paraptosis.
    Lee DM; Kim IY; Lee HJ; Seo MJ; Cho MY; Lee HI; Yoon G; Ji JH; Park SS; Jeong SY; Choi EK; Choi YH; Yun CO; Yeo M; Kim E; Choi KS
    Cell Death Dis; 2024 Jan; 15(1):48. PubMed ID: 38218922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Valosin-Containing Protein (VCP)/p97: A Prognostic Biomarker and Therapeutic Target in Cancer.
    Costantini S; Capone F; Polo A; Bagnara P; Budillon A
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AAA ATPase p97/valosin-containing protein interacts with gp78, a ubiquitin ligase for endoplasmic reticulum-associated degradation.
    Zhong X; Shen Y; Ballar P; Apostolou A; Agami R; Fang S
    J Biol Chem; 2004 Oct; 279(44):45676-84. PubMed ID: 15331598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction between salt-inducible kinase 2 (SIK2) and p97/valosin-containing protein (VCP) regulates endoplasmic reticulum (ER)-associated protein degradation in mammalian cells.
    Yang FC; Lin YH; Chen WH; Huang JY; Chang HY; Su SH; Wang HT; Chiang CY; Hsu PH; Tsai MD; Tan BC; Lee SC
    J Biol Chem; 2013 Nov; 288(47):33861-33872. PubMed ID: 24129571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VCP/p97/Cdc48, A Linking of Protein Homeostasis and Cancer Therapy.
    Lan B; Chai S; Wang P; Wang K
    Curr Mol Med; 2017; 17(9):608-618. PubMed ID: 29521227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional ATPase activity of p97/valosin-containing protein (VCP) is required for the quality control of endoplasmic reticulum in neuronally differentiated mammalian PC12 cells.
    Kobayashi T; Tanaka K; Inoue K; Kakizuka A
    J Biol Chem; 2002 Dec; 277(49):47358-65. PubMed ID: 12351637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of a novel p97/valosin-containing protein-interacting motif of gp78 in endoplasmic reticulum-associated degradation.
    Ballar P; Shen Y; Yang H; Fang S
    J Biol Chem; 2006 Nov; 281(46):35359-68. PubMed ID: 16987818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The functional importance of VCP to maintaining cellular protein homeostasis.
    Ahlstedt BA; Ganji R; Raman M
    Biochem Soc Trans; 2022 Oct; 50(5):1457-1469. PubMed ID: 36196920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. VCP inhibitors induce endoplasmic reticulum stress, cause cell cycle arrest, trigger caspase-mediated cell death and synergistically kill ovarian cancer cells in combination with Salubrinal.
    Bastola P; Neums L; Schoenen FJ; Chien J
    Mol Oncol; 2016 Dec; 10(10):1559-1574. PubMed ID: 27729194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathogenic Mutations in the Valosin-containing Protein/p97(VCP) N-domain Inhibit the SUMOylation of VCP and Lead to Impaired Stress Response.
    Wang T; Xu W; Qin M; Yang Y; Bao P; Shen F; Zhang Z; Xu J
    J Biol Chem; 2016 Jul; 291(27):14373-14384. PubMed ID: 27226613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of ER-associated degradation via p97/VCP-interacting motif.
    Ballar P; Fang S
    Biochem Soc Trans; 2008 Oct; 36(Pt 5):818-22. PubMed ID: 18793143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selenoprotein S-dependent Selenoprotein K Binding to p97(VCP) Protein Is Essential for Endoplasmic Reticulum-associated Degradation.
    Lee JH; Park KJ; Jang JK; Jeon YH; Ko KY; Kwon JH; Lee SR; Kim IY
    J Biol Chem; 2015 Dec; 290(50):29941-52. PubMed ID: 26504085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inclusion body myopathy-associated mutations in p97/VCP impair endoplasmic reticulum-associated degradation.
    Weihl CC; Dalal S; Pestronk A; Hanson PI
    Hum Mol Genet; 2006 Jan; 15(2):189-99. PubMed ID: 16321991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VCP/p97 mediates nuclear targeting of non-ER-imported prion protein to maintain proteostasis.
    Banik P; Ray K; Kamps J; Chen QY; Luesch H; Winklhofer KF; Tatzelt J
    Life Sci Alliance; 2024 Jun; 7(6):. PubMed ID: 38570188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining valosin-containing protein (VCP) inhibition and suberanilohydroxamic acid (SAHA) treatment additively enhances the folding, trafficking, and function of epilepsy-associated γ-aminobutyric acid, type A (GABAA) receptors.
    Han DY; Di XJ; Fu YL; Mu TW
    J Biol Chem; 2015 Jan; 290(1):325-37. PubMed ID: 25406314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ATPase activity of p97/valosin-containing protein is regulated by oxidative modification of the evolutionally conserved cysteine 522 residue in Walker A motif.
    Noguchi M; Takata T; Kimura Y; Manno A; Murakami K; Koike M; Ohizumi H; Hori S; Kakizuka A
    J Biol Chem; 2005 Dec; 280(50):41332-41. PubMed ID: 16234241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRSK2 is a valosin-containing protein (VCP)-interacting protein that affects VCP functioning in endoplasmic reticulum-associated degradation.
    Wang Y; Wan B; Zhou J; Li R; Yu L
    Biotechnol Lett; 2013 Dec; 35(12):1983-9. PubMed ID: 23907667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel p97/VCP inhibitor induces endoplasmic reticulum stress and apoptosis in both bortezomib-sensitive and -resistant multiple myeloma cells.
    Nishimura N; Radwan MO; Amano M; Endo S; Fujii E; Hayashi H; Ueno S; Ueno N; Tatetsu H; Hata H; Okamoto Y; Otsuka M; Mitsuya H; Matsuoka M; Okuno Y
    Cancer Sci; 2019 Oct; 110(10):3275-3287. PubMed ID: 31368616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Valosin-containing Protein (VCP)/p97 Segregase Mediates Proteolytic Processing of Cockayne Syndrome Group B (CSB) in Damaged Chromatin.
    He J; Zhu Q; Wani G; Sharma N; Wani AA
    J Biol Chem; 2016 Apr; 291(14):7396-408. PubMed ID: 26826127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A functional deficiency of TERA/VCP/p97 contributes to impaired DNA repair in multiple polyglutamine diseases.
    Fujita K; Nakamura Y; Oka T; Ito H; Tamura T; Tagawa K; Sasabe T; Katsuta A; Motoki K; Shiwaku H; Sone M; Yoshida C; Katsuno M; Eishi Y; Murata M; Taylor JP; Wanker EE; Kono K; Tashiro S; Sobue G; La Spada AR; Okazawa H
    Nat Commun; 2013; 4():1816. PubMed ID: 23652004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.